Saturday, June 20, 2026

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,771
Drugs linked 4,798

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 823 of 1,261
  1. US 8691828

    Thienopyrimidine as CDC7 kinase inhibitors

    Takeda Pharmaceutical Company Limited · Granted Apr 8, 2014 · Expires Apr 3, 2034

    granted
  2. US 8691963

    Delivering functional nucleic acids to mammalian cells via bacterially-derived, intact minicells

    EnGeneIC Molecular Delivery Pty Ltd · Granted Apr 8, 2014 · Expires Apr 3, 2034

    granted
  3. US 8691943

    Antimicrobial activity of chicken NK-2 peptide against apicomplexan protozoa

    The United States of America, as represented by the Secretary of Agriculture · Granted Apr 8, 2014 · Expires Apr 3, 2034

    granted
  4. US 8691872

    Dispersions of rasagiline citrate

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Apr 8, 2014 · Expires Apr 3, 2034

    granted
  5. US 8691967

    Multiple promoter expression cassettes for simultaneous delivery of RNAi agents

    Benitec, Inc. · Granted Apr 8, 2014 · Expires Apr 3, 2034

    granted
  6. US 8692051

    Methods for testing for caloric restriction (CR) mimetics

    BioMarker Pharmaceuticals, Inc. · Granted Apr 8, 2014 · Expires Apr 3, 2034

    granted
  7. US 8691852

    Amino nicotinic and isonicotinic acid derivatives as DHODH inhibitors

    Amirall, S.A. · Granted Apr 8, 2014 · Expires Apr 3, 2034

    granted
  8. US 8691849

    3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors

    Addex Pharma, S.A. · Granted Apr 8, 2014 · Expires Apr 3, 2034

    granted
  9. US 8691831

    Heterocyclic aspartyl protease inhibitors

    Pharmacopeia Drug Discovery, Inc. · Granted Apr 8, 2014 · Expires Apr 3, 2034

    granted
  10. US 8691184

    Bcl-2/Bcl-xL inhibitors and therapeutic methods using the same

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Apr 8, 2014 · Expires Apr 3, 2034

    granted
  11. AU 2012308663

    Formulations of cyclopropanecarboxylic acid {2-[1S)-1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1H-isoindol-4-yl}-amidecelgene corporation state of incorporation:delaware

    CELGENE CORP [CH] · Granted Apr 3, 2014 · Expires Mar 29, 2034

    granted
  12. US 8685924

    Preventives/remedies for stress urinary incontinence and method of screening the same

    Takeda Pharmaceutical Company Limited · Granted Apr 1, 2014 · Expires Mar 27, 2034

    granted
  13. US 8685936

    Sphingosine kinase inhibitor prodrugs

    Apogee Biotechnology Corporation · Granted Apr 1, 2014 · Expires Mar 27, 2034

    granted
  14. US 8686143

    Compounds useful as inhibitors of Janus kinases

    Vertex Pharmaceuticals Incorporated · Granted Apr 1, 2014 · Expires Mar 27, 2034

    granted
  15. US 8686157

    Processes for the facile synthesis of diaryl amines and analogues thereof

    Vertex Pharmaceuticals Incorporated · Granted Apr 1, 2014 · Expires Mar 27, 2034

    granted
  16. US 8686045

    Methods of facilitating neural cell survival using non-peptide and peptide BDNF neurotrophin mimetics

    The Regents of the University of California · Granted Apr 1, 2014 · Expires Mar 27, 2034

    granted
  17. US 8686041

    Inhibition of ornithine aminotransferase for the treatment of proliferative disorders

    Northwestern University · Granted Apr 1, 2014 · Expires Mar 27, 2034

    granted
  18. US 8685932

    Targeted transforming growth factor-beta-bound IgG for Treatment of Diseases

    OPTION PHARMACEUTICALS, LLC · Granted Apr 1, 2014 · Expires Mar 27, 2034

    granted
  19. US 8685926

    Compositions and method for CaMKII inhibitors and uses thereof

    The Regents of the University of Colorado, a Body Corporate · Granted Apr 1, 2014 · Expires Mar 27, 2034

    granted
  20. US 8685404

    Recombinant T-cell receptor ligand for the treatment of cognitive and neuropsychiatric impairment induced by substance addiction

    United States Government as represented by the Department of Veterans Affairs · Granted Apr 1, 2014 · Expires Mar 27, 2034

    granted
  21. US 8686184

    Neprilysin inhibitors

    Theravance, Inc. · Granted Apr 1, 2014 · Expires Mar 27, 2034

    granted
  22. US 8685979

    Oligomer-diarylpiperazine conjugates

    Nektar Therapeutics · Granted Apr 1, 2014 · Expires Mar 27, 2034

    granted
  23. US 8686012

    Stem cell differentiating agents and uses therefor

    The Board of Regents of the University of Texas System · Granted Apr 1, 2014 · Expires Mar 27, 2034

    granted
  24. US 8686016

    Schweinfurthins and uses thereof

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Apr 1, 2014 · Expires Mar 27, 2034

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.